Cargando…
Rationale, design, and methodology of a trial evaluating three models of care for HCV treatment among injection drug users on opioid agonist therapy
BACKGROUND: People who inject drugs (PWID) constitute 60% of the approximately 5 million people in the U.S. infected with hepatitis C virus (HCV). Treatment of PWID is complex due to addiction, mental illness, poverty, homelessness, lack of positive social support, poor adherence-related skills, low...
Autores principales: | Akiyama, Matthew J., Agyemang, Linda, Arnsten, Julia H., Heo, Moonseong, Norton, Brianna L., Schackman, Bruce R., Linas, Benjamin P., Litwin, Alain H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5807730/ https://www.ncbi.nlm.nih.gov/pubmed/29426304 http://dx.doi.org/10.1186/s12879-018-2964-5 |
Ejemplares similares
-
Factors and HCV treatment outcomes associated with smoking among people who inject drugs on opioid agonist treatment: secondary analysis of the PREVAIL randomized clinical trial
por: Pericot-Valverde, Irene, et al.
Publicado: (2020) -
Declines in Depressive Symptoms Among People who Inject Drugs Treated With Direct-Acting Antivirals While on Opioid Agonist Therapy
por: Pericot-Valverde, Irene, et al.
Publicado: (2020) -
Low Adherence Achieves High HCV Cure Rates Among People Who Inject Drugs Treated With Direct-Acting Antiviral Agents
por: Norton, Brianna L, et al.
Publicado: (2020) -
More intensive hepatitis C virus care models promote adherence among people who inject drugs with active drug use: The PREVAIL study
por: Heo, Moonseong, et al.
Publicado: (2022) -
Artificial Intelligence Platform Demonstrates High Adherence in Patients Receiving Fixed-Dose Ledipasvir and Sofosbuvir: A Pilot Study
por: Litwin, Alain H, et al.
Publicado: (2020)